Hepatocellular carcinoma

Global Liver Cancer Drug (Targeted Therapy, Immunotherapy, Chemotherapy) Market Size, Share & Trends Analysis Report 2023-2030 Featuring Bayer, Bristol-Myers Squibb, Eisai, Exelixis, and Merck - ResearchAndMarkets.com

Retrieved on: 
Tuesday, January 2, 2024
Pharmaceutical, Genetics, Health, Oncology, RNA, Targeted therapy, RNA interference, Quality of life, Death, Hepatocellular carcinoma, Mortality, Incidence, Cirrhosis, Cancer, HCC, USD, Liver cancer, Traction, Growth, Patient, Potyvirus, Therapy, Dietary supplement

The "Liver Cancer Drug Market Size, Share & Trends Analysis Report By Drug Class (Targeted Therapy, Immunotherapy, Chemotherapy), By Region, And Segment Forecasts, 2023 - 2030" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Liver Cancer Drug Market Size, Share & Trends Analysis Report By Drug Class (Targeted Therapy, Immunotherapy, Chemotherapy), By Region, And Segment Forecasts, 2023 - 2030" report has been added to ResearchAndMarkets.com's offering.
  • Widening base of liver cancer patients can be attributed to unhealthy lifestyles and growing geriatric population.
  • This, in turn, is working in favor of the liver cancer therapeutics market.
  • In 2012, 782,451 new cases of liver cancer were diagnosed, and 745,533 deaths were reported due to liver cancer.

Eisai and Merck & Co., Inc., Rahway, NJ, USA Provide Update on Phase 3 LEAP-001 Trial Evaluating LENVIMA (lenvatinib) Plus KEYTRUDA (pembrolizumab) as First-Line Treatment for Patients with Advanced or Recurrent Endometrial Carcinoma

Retrieved on: 
Monday, December 11, 2023
MSD, Pembrolizumab, Stomach, Lenvatinib, Hepatocellular carcinoma, Research, Carboplatin, Progression-free survival, MSI-H, Disease, Merck & Co., Standard of care, Head, RCC, Cancer, Merck, Patient, OS, PFS, Eisai, Paclitaxel, Esophageal cancer, LEAP, Senior, Pharmaceutical industry

The safety profile of LENVIMA plus KEYTRUDA was consistent with that observed in previously reported studies evaluating the combination.

Key Points: 
  • The safety profile of LENVIMA plus KEYTRUDA was consistent with that observed in previously reported studies evaluating the combination.
  • We are grateful to the patients, their loved ones, and the investigators whose participation is what makes scientific advancement possible."
  • LENVIMA plus KEYTRUDA is approved in the U.S., the EU, Japan and other countries for the treatment of certain types of advanced endometrial carcinoma following prior systemic therapy in any setting and advanced renal cell carcinoma (RCC).
  • Results from the LEAP-001 trial do not affect the current approved indications for the KEYTRUDA plus LENVIMA combination or other ongoing trials from the LEAP clinical program.

VinBrain to Launch AI-centric Solutions to Save Lives and Advance Precision Care at RSNA 2023

Retrieved on: 
Monday, December 4, 2023
Cloud, Liver, Radiology, Microsoft Band, Life expectancy, Stanford University, Cancer, Vingroup, Diagnosis, Microsoft, Hepatocellular carcinoma, Artificial intelligence, SOTA, EDS, Privacy, Exhibition, Knowledge, Fellow, Azure, Health care, Scientific Reports, Medical imaging, Physician, Tuberculosis, HCC, CXR, AI, TACE, HIPAA, Patient, Medicine, NVIDIA, TB, TME, HIS, Learning, Research, R&D, RIS, PACS, EMR, NIST, Health, Graphics processing unit, RSNA, Medical device

Unveiling two impactful AI-centric solutions during the event - DrAid Enterprise Data Solution: Centralization, Transformation, Intelligence; and DrAid Oncology Diagnosis and Treatment, VinBrain takes major steps forward in innovation, aiming to save more lives and advance precision care for everyone.

Key Points: 
  • Unveiling two impactful AI-centric solutions during the event - DrAid Enterprise Data Solution: Centralization, Transformation, Intelligence; and DrAid Oncology Diagnosis and Treatment, VinBrain takes major steps forward in innovation, aiming to save more lives and advance precision care for everyone.
  • Expediting interoperability and streamlining, DrAid Enterprise Data Solution (EDS) is hoped to lead the healthcare transformation towards precision care.
  • Dr. Michael C. Muelly, medical partner of VinBrain shared his point of view about clinical practices and values of the solutions during product launch at RSNA 2023.
  • At RSNA 2023, VinBrain also showcased its commitment to providing accessible healthcare in underserved regions with high tuberculosis burden through DrAid for Tuberculosis Screening (CXR Screening).

Bristol Myers Squibb Adds Premier Radiopharmaceutical Platform with Acquisition of RayzeBio

Retrieved on: 
Tuesday, December 26, 2023
Actinium, Hart–Scott–Rodino Antitrust Improvements Act, BMY, SSTR2, Bristol Myers Squibb, Hepatocellular carcinoma, Drug development, LLP, Acquisition, Centerview Partners, SAN, Carcinoma, BofA Securities, HCC, Covington & Burling, GMP, Cancer, CA9, Growth, Patient, Therapy, GPC3, Radioactive decay, Cooley LLP, Radiation, Pharmaceutical industry

PRINCETON, N.J. and SAN DIEGO, Dec. 26, 2023 (GLOBE NEWSWIRE) -- Bristol Myers Squibb (NYSE: BMY) and RayzeBio, Inc. (NASDAQ: RYZB) today announced a definitive merger agreement under which Bristol Myers Squibb will acquire RayzeBio for $62.50 per share in cash, for a total equity value of approximately $4.1 billion, or $3.6 billion net of estimated cash acquired. The transaction was unanimously approved by both the Bristol Myers Squibb and RayzeBio Boards of Directors.

Key Points: 
  • The transaction was unanimously approved by both the Bristol Myers Squibb and RayzeBio Boards of Directors.
  • “Radiopharmaceutical therapeutics are already transforming cancer care, and RayzeBio is at the forefront of pioneering the application of this novel modality.
  • Bristol Myers Squibb expects to finance the acquisition with primarily new debt issuance.
  • BofA Securities, Inc., is serving as financial advisor to Bristol Myers Squibb, and Covington & Burling LLP is serving as legal counsel.

Polaris Group Announced the Acquisition of Genovior Biotech, Initiating Dual-Engine Growth

Retrieved on: 
Friday, December 22, 2023
Mesothelioma, Workforce, Leiomyosarcoma, Hepatocellular carcinoma, Acquisition, Semaglutide, MIT, Diabetes, Chemical engineering, SAN, Biologics license application, HCC, Glioblastoma, Dicarboxylic acid, Doctor of Philosophy, GBM, LMS, Growth, Escherichia coli, BLA

TAIPEI, Taiwan and SAN DIEGO, Dec. 21, 2023 (GLOBE NEWSWIRE) -- Polaris Group (The Company, TWSE:6550) announced that its board approved to increase the acquisition of Genovior Biotech's shares to 100%.

Key Points: 
  • TAIPEI, Taiwan and SAN DIEGO, Dec. 21, 2023 (GLOBE NEWSWIRE) -- Polaris Group (The Company, TWSE:6550) announced that its board approved to increase the acquisition of Genovior Biotech's shares to 100%.
  • Additionally, Dr. Steve Hsu, Chairman of Genovior Biotech Corporation, has been appointed as the CEO of Polaris Group.
  • These two highly prospective product lines will serve as the dual engines propelling Polaris Group's future growth.
  • Consequently, Genovior Biotech fills critical gaps for Polaris Group, providing not just high-quality manufacturing capabilities but also a substantial entry into the market for peptide products.

Affimed Announces Positive Data for AFM24 in Combination with the PD-L1 Checkpoint Inhibitor Atezolizumab in Heavily Pre-treated EGFR-Wildtype Non-Small Cell Lung Cancer Patients

Retrieved on: 
Monday, December 11, 2023
Stomach, EST, Hepatocellular carcinoma, RECIST, EGFR, Progression-free survival, Cancer, Pancreatic cancer, Toxicity, Cholangiocarcinoma, Webcast, Patient, Safety, NSCLC, Pharmaceutical industry

The data update as of December 6th, 2023, includes 15 patients from the EGFR-wildtype NSCLC cohort with a median of 2 prior lines of therapy.

Key Points: 
  • The data update as of December 6th, 2023, includes 15 patients from the EGFR-wildtype NSCLC cohort with a median of 2 prior lines of therapy.
  • The combination of AFM24 with atezolizumab showed encouraging signals of clinical activity, including 1 unconfirmed CR, 3 PRs (1 confirmed, 2 unconfirmed) and 7 patients exhibiting SD.
  • Considering the low ORR reported on atezolizumab monotherapy in checkpoint inhibitor-relapsing and refractory patients, Affimed believes the clinical activity observed in AFM24-102 is likely due to the synergy of AFM24 with atezolizumab.
  • AFM24 has demonstrated a positive safety and tolerability profile as both a monotherapy and in combination therapy.

HUTCHMED Highlights Clinical Data to be Presented at 2023 ESMO Asia and ESMO Immuno-Oncology Congresses

Retrieved on: 
Friday, December 1, 2023
Stomach, Hepatocellular carcinoma, VEGFR, Cervical cancer, PD-1, Renal cell carcinoma, Endometrial cancer, Sintilimab, HCC, GC, RCC, Patient, Safety, EMC, NSCLC, BSC, Pharmaceutical industry

These presentations will report results from the cervical cancer and NSCLC patient cohorts of the basket clinical trial in China of fruquintinib plus sintilimab.

Key Points: 
  • These presentations will report results from the cervical cancer and NSCLC patient cohorts of the basket clinical trial in China of fruquintinib plus sintilimab.
  • Data from the EMC and RCC cohorts of this trial led to the initiation of registration enabling programs.
  • This combination treatment showed promising antitumor activity in advanced cervical cancer and NSCLC patients, particularly for patients with PD-L1 positive status.
  • Fruquintinib is a selective oral inhibitor of vascular endothelial growth factor receptors (“VEGFR”) -1, -2 and -3.

 Bristol Myers Squibb Adds Premier Radiopharmaceutical Platform with Acquisition of RayzeBio

Retrieved on: 
Tuesday, December 26, 2023
Biotechnology, Health, Pharmaceutical, Clinical Trials, Oncology, Actinium, Hart–Scott–Rodino Antitrust Improvements Act, BMY, SSTR2, Bristol Myers Squibb, Hepatocellular carcinoma, Multimedia, Drug development, LLP, Acquisition, Centerview Partners, Carcinoma, BofA Securities, HCC, Covington & Burling, GMP, Cancer, CA9, Growth, Patient, Therapy, GPC3, Radioactive decay, Cooley LLP, Radiation, Pharmaceutical industry

Bristol Myers Squibb (NYSE: BMY) and RayzeBio, Inc. (NASDAQ: RYZB) today announced a definitive merger agreement under which Bristol Myers Squibb will acquire RayzeBio for $62.50 per share in cash, for a total equity value of approximately $4.1 billion, or $3.6 billion net of estimated cash acquired.

Key Points: 
  • Bristol Myers Squibb (NYSE: BMY) and RayzeBio, Inc. (NASDAQ: RYZB) today announced a definitive merger agreement under which Bristol Myers Squibb will acquire RayzeBio for $62.50 per share in cash, for a total equity value of approximately $4.1 billion, or $3.6 billion net of estimated cash acquired.
  • The transaction was unanimously approved by both the Bristol Myers Squibb and RayzeBio Boards of Directors.
  • Bristol Myers Squibb expects to finance the acquisition with primarily new debt issuance.
  • BofA Securities, Inc., is serving as financial advisor to Bristol Myers Squibb, and Covington & Burling LLP is serving as legal counsel.

Boston Pharmaceuticals Appoints Juan Carlos Lopez-Talavera, MD, PhD, as Acting Chief Medical Officer as MASH Asset BOS-580 Accelerates in Phase 2 Clinical Program

Retrieved on: 
Tuesday, December 19, 2023
Biotechnology, Pharmaceutical, Health, Clinical Trials, Yale University, Doctor of Pharmacy, Hepatocellular carcinoma, Pharmacy, CMO, Roche, Medication, Bristol Myers Squibb, Hepatology, Intercept Pharmaceuticals, Doctor of Philosophy, Nobel Prize, HCV, University, Fatty liver disease, Knowledge, MASH, AbbVie, Acting, Pharmaceutical industry

Boston Pharmaceuticals today announced the appointment of Juan Carlos Lopez-Talavera, M.D., Ph.D., as Acting Chief Medical Officer (CMO).

Key Points: 
  • Boston Pharmaceuticals today announced the appointment of Juan Carlos Lopez-Talavera, M.D., Ph.D., as Acting Chief Medical Officer (CMO).
  • Boston Pharmaceuticals is a clinical stage biopharmaceutical company with a lead investigational asset in non-alcoholic steatohepatitis (MASH), BOS-580, currently in Phase 2 development, and a Phase 1 asset, BOS-342, in development for hepatocellular carcinoma.
  • Dr. Lopez-Talavera joined Boston Pharmaceuticals in August 2023 and has since been instrumental in accelerating the development of BOS-580, which will advance to pivotal studies in 2024.
  • He completed a post-doctoral fellowship at Yale University and served as an Assistant Professor at the University of Pittsburgh.

Alnylam Highlights Significant Progress with Platform Innovation and Clinical Pipeline at R&D Day

Retrieved on: 
Wednesday, December 13, 2023
Biotechnology, Health, Genetics, Pharmaceutical, Clinical Trials, CNS, Hypertension, Cerebral amyloid angiopathy, Hepatocellular carcinoma, Gene, ALN, Cardiomyopathy, RNA interference, IND, Tissue, Liver, Sanofi, Amyloidosis, Gene silencing, Overweight, KHK, Patient, FGF21, CAA, Part, Obesity, T2DM, Neoplasm, Investigational New Drug, Therapy, LNP, Development, Shanda, Growth, HCC, Central nervous system, Type, TTR, Immunotherapy, Polyneuropathy, Haemophilia, Medication, Biology, Coagulopathy, Traffic barrier, Adipose tissue, Vaccine, Medical device, Pharmaceutical industry, Video game, Alnylam Pharmaceuticals, Capella, ATTR

We expect our track record of strong pipeline and commercial execution to continue through the end of 2025 and beyond,” said Akshay Vaishnaw, M.D., Ph.D., Chief Innovation Officer of Alnylam.

Key Points: 
  • We expect our track record of strong pipeline and commercial execution to continue through the end of 2025 and beyond,” said Akshay Vaishnaw, M.D., Ph.D., Chief Innovation Officer of Alnylam.
  • In addition, Alnylam will share an update on delivery advances driving ALN-BCAT, which will soon begin clinical testing in patients with hepatocellular carcinoma (HCC).
  • A peak mean TTR reduction of 97% was achieved at Day 29 and a mean TTR reduction of 93% was sustained at Day 180.
  • The Company’s R&D Day event will be held today, Wednesday, Dec. 13, from 8:30 a.m. to 12:45 p.m.